drugset
drugset / Trial / NCT01322594

A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease

NCT01322594 ↗

Phase 1 Completed 31 enrolled MedImmune LLC
RandomizedSingle-groupSingle-blindTreatment

Summary

Phase I study to evaluate the safety and tolerability of single ascending intravenous doses of MEDI2338 in subjects with stable, mild to moderate chronic obstructive pulmonary disease (COPD).

Timeline

Start
2011-03
Primary completion
2011-11
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Camoteskimab Monoclonal antibody 10 mg Intravenous
Subject Camoteskimab Monoclonal antibody 30 mg Intravenous
Subject Camoteskimab Monoclonal antibody 100 mg Intravenous
Subject Camoteskimab Monoclonal antibody 300 mg Intravenous
Subject Camoteskimab Monoclonal antibody 1000 mg Intravenous

Indications

chronic obstructive pulmonary disease